The New BioPharma Playbook: Seven Technologies Defining Drug Development in 2026
From multifunctional antibodies and T-cell engagers to in vivo cell therapies and hepatitis B functional cures, the most important large-molecule therapies of 2026 reveal the technological trends driving the next generation of biologic medicines.
A common theme emerging across oncology, infectious disease, neurology, and cell therapy, is the evolution of biopharmaceuticals from single-function molecules into increasingly sophisticated therapeutic platforms capable of performing multiple tasks simultaneously. Some deliver cytotoxic payloads directly into cancer cells. Others engage multiple immune pathways through a single antibody. Still others program immune cells inside the body or cross biological barriers that have historically limited treatment options.